Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUHURO: Tigecycline in Urogenital Cancers
NCT03962920Recruiting
- Sponsor
- Zealand University Hospital
- Start
- May 2020
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, single-blind trial in genitourinary cancer comparing Tigecycline Arm with Placebo Arm (2 arms). Primary endpoint: Recurrence rate after surgical treatment of tumour at 5 years. Started May 2020; status: recruiting.
02
Drugs
tigecycline
03
Conditions
genitourinary cancer
Beyond the preview
Go deeper on NCT03962920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03962920.